QualityDipStocks / Health Care · Ophthalmic Goods
STAAR Surgical Company STAA
Outside our quality screen, so we don’t track its dips. It’s 25% below its 52-week high.
Outside our quality screen, 10% over its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 30% from its 52-week high while revenue grew 51%
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $22.63price +10%
- Off 52-wk high
- −25%
- Risk vs market
- Lowbeta 0.24
52-week range 51% of the way from its 52-week low to its high
Price $24.94Market Value $22.63
3 bullish · 5 bearish See why
Repriced or dip?
Dip: business intact
The price is 25% below its 52-week high (May 26), but the business held up: revenue +16.9%, revenue growth rate +47.3 pts, earnings per share turned to a profit.
Some numbers held up (revenue +16.9%, revenue growth rate +47.3 pts, earnings per share turned to a profit), others slipped. The price is 25% below its 52-week high.
The price is 25% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 7 numbers, high vs now
- Revenue, last 12 months$290M → $340M (+16.9%)held up
- Revenue growth rate+4.0% → +51.3% a year (+47.3 pts)held up
- Earnings per share, 12 monthsturned to a profitheld up
- Operating margin−9.1% → 4.0% (+13.1 pts)held up
- Shares outstanding+2.4% (more shares, each owns less)about the same
- Stock vs its sector (Health Care)stock −25%, sector median +17% since May 26changed
- Price fall vs business numbersprice −25%, revenue/EPS/FCF median +17% (shown, not scored)
Business numbers as reported at the high (12 months to Apr 3, 2026) vs the latest filing (12 months to Jul 3, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
Now: P/E 338.6×.
| High | Low | Now | |
|---|---|---|---|
| Price | $33.34May 26 | $16.10Feb 13 | $24.94 |
| Implied growth | n/a | n/a | n/a |
| P/E | n/a | n/a | 338.6× |
What this means: a lower P/E than at the high means you pay less for each dollar of profit than buyers did then.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for STAA: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much STAA moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 4.3× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.24
- Volatility
- 55% vs 13% SPY
- Correlation SPY
- 0.06
- Correlation QQQ
- 0.04
How it ranks
Where STAA stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 4 measures
- Free cash flow yield−0.5% · free cash flow vs market capLowest 18%of 1,690
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 2,227
- Revenue growth, last 12 months+51% · vs the 12 months beforeTop 7%of 2,184
- Operating margin4% · of sales kept as operating profitLowest 26%of 1,549
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $22.63
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
GrowthSales grew 51% to $340M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityGross margin of 77%, above the 65% median for the 195 Health Care companies we cover.
ValuationPrice / book of 3.6×, below the 4.8× median for the 291 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$7M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityOperating margin narrowed to −38.3% in FY2026 from 8.7% in FY2023 (SEC filings).
ProfitabilityReturn on equity fell 29 points in two fiscal years, to -23% in FY2026.
QualityDoesn’t pass our quality screen: no positive free cash flow.
ValuationTrades 10.2% above its Market Value of $22.63, the average price paid since the Aug 12 filing.
All fundamentals
FCF yield -0.5% · ROE 1% · Sales +51%
Valuation
- P/E
- n/an/m: earnings near zero (P/E above 300)
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −0.5%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 3.83×
- Price / book
- 3.56×
- Market cap
- $1.3Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $340M
- Sales growth, 12 months
- +51.3%vs the 12 months before
- Sales growth, 3 yrs
- 0.0%/yrfrom FY2022
- Diluted EPS, 12 months
- $0.08
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $4M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 76.6%
- Operating margin
- 4.0%
- Net margin
- 1.1%
- FCF margin
- −2.0%
- Return on equity
- 1%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $181M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$7M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +4.0%diluted shares vs a year ago
- Stock-based comp
- $28M
Trailing 12 months to Jul 3, 2026; balance sheet at Jul 3, 2026. From STAAR Surgical Company’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.0B · Sales +111%
- Free cash flow, 12 months−$0.0B
- Free-cash-flow yield-0.5%
- Gross margin77%
- Operating margin11%
- Return on invested capital13%
- Return on equity1%
- Sales growth (latest quarter vs year-ago quarter)+111%
- Net debt / EBITDA−2.9×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $24.94
- 52-wk lowlowest close, 1 year$16.10−35.4%
- Market Valueavg paid since Aug 12$22.63−9.3%
- PriceMon Nov 2 close$24.94you are here
- 52-wk highhighest close, 1 year$33.34+33.7%
Momentum & 52-week range
RSI 64 · 5 days +7.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4, after the close
- Consensus EPS$0.05
- Year-ago EPS$0.30
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
STAA is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on STAAR Surgical Company in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Ophthalmic Goods
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.